David Berg – Fibroblast Growth Factor-23, Cardiorenal Outcomes, and Efficacy of Dapagliflozin in Patients with T2DM-An analysis from DECLARE-TIMI 58
David Berg – Assessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus
Brian Bergmark – TRANSLATE-TIMI 70
DOAC Use is Safe and Effective for Patients with AF and Reduced Renal Function-Results from COMBINE-AF
Antonio Fagundes, Jr. – Neutrophil-Lymphocyte Ratio and Outcomes in Patients with AF-Analyses from ENGAGE AF-TIMI 48
Ryan Keane – Characteristics and Outcomes of Adults with Congenital Heart Disease in the CICU-Insights from the Critical Care Cardiology Trials Network (CCCTN)
Mathew Lopes – Targeted Proteomic Profiling of Cardiogenic Shock in the Cardiac Intensive Care Unit-An Analysis from the CCCTN
Thomas Metkus – Cardiac Surgical Therapy in the Contemporary CICU-Implications for the Heart Team, from CCCTN
Kazuma Oyama – Serial Assessment of Biomarkers and the Risk of Heart Failure in Patients
Siddharth Patel – Clinician and Algorithmic Application of the 2019 and 2022 SCAI Shock Stages in the CCCTN
Balim Senman – Circulating Biomarker Patterns in Patients with Vasodilatory Cardiogenic Shock in the Cardiac Intensive Care Unit-Analysis from the CCCTN Registry
Ankeet Bhatt – Multi-Marker Risk Assessment in Patients Hospitalized with COVID-19
David Berg – High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with HFrEF. An Analysis of Serial Assessment in the DAPA-HF Trial.
Aditya Dewanjee – Elucidating Clinical Phenotypes of Patients with Mixed Shock Admitted to Cardiac Intensive Care Units. Insights from the Critical Care Cardiology Trial.
Amanda Garfinkel – Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease
Baris Gencer – Clinical Safety Outcomes in Relation to Lipoprotein(a) Concentration. Insights from the FOURIER trial
Jingyi Gong – Predictive value of echocardiographic markers of diastolic dysfunction for heart failure in overweight and obese patients in CAMELLIA-TIMI 61
Nicholas Marston – ApoB-containing Lipoproteins and Risk of Myocardial Infarction. Distinguishing between Particle Concentration, Type, and Content.
Nicholas Marston – Predictive Utility of a CAD Polygenic Risk Score in Primary Prevention Based on Age and Clinical Risk
Filipe Moura – Dapagliflozin and Changes in Metabolic Syndrome in Patients with Type 2 Diabetes. A DECLARE TIMI 58 Sub-analysis.
Siddharth Patel – A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease
Siddharth Patel – A Targeted Proteomic Approach Identifies Novel Biomarkers Associated With Risk of Myocardial Infarction in Post-Menopausal Women
Siddharth Patel – Evaluation of the ABC Pathway for Comprehensive Management of Atrial Fibrillation in 20,933 Patients from the ENGAGE AF-TIMI 48 Trial
Siddharth Patel – Ezetimibe Consistently Reduces LDL-C with Little Interindividual Variability in 14,970 Patients Post-ACS
Marc Sabatine – PCI with Drug-Eluting Stents vs. CABG in Left Main Coronary Artery Disease. An Individual Patient Data Meta-Analysis.
Kazuma Oyama – Acute arterial events across all vascular territories in the FOURIER trial
Nicholas Marston – Cardiovascular Benefit of Lowering LDL-C Below ~1 mmol per L (40 mg per dl)
David Berg – High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction-An Analysis of the DAPA-HF Trial
Kazuma Oyama – Influence of Cardiovascular Drugs on the Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in DECLARE-TIMI 58
Robert Semco – Epistaxis in Anticoagulated Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
Raffaele de Caterina – Effectiveness and Safety of Edoxaban in Atrial Fibrillation Patients from the ETNA-AF Global Registry
Carlos Alviar – Clinical Characteristics And Outcomes Of Older Patients In Cardiac Intensive Care Units- From The Critical Care Cardiology Trials Network Registry
David Berg – A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48
David Berg – Mediation Analysis for Dapagliflozin and the Reduction in Hospitalization for Heart Failure in DECLARE-TIMI 58
Ankeet Bhatt – De Novo vs. Acute-on-Chronic Presentations of Heart Failure Associated Cardiogenic Shock in CICUs Data From the Critical Care Cardiology Trials Network
Marc Bonaca – Cardioprotection and Plaque Regression with MEDI6012 in Acute ST Elevation Myocardial Infarction – Primary Results of the Phase 2B REAL-TIMI 63B Randomized Clinical Trial
Antonio Fagundes, Jr. – Biomarker prediction of major coronary events and complex revascularization procedures in patients with stable atherosclerosis